Axonics Modulation Technologies, Inc. (AXNX)
Stock Price:
$40.86 USD
0.44 (1.09%)
Updated Jul 9, 2020 2:51 PM EDT - Market open
Key Info
| Market Cap |
1.41B |
| Revenue (ttm) |
39.04M |
| Net Income (ttm) |
-81.43M |
| Shares Out |
39.12M |
| EPS (ttm) |
-2.71 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 9, 2020 |
| Last Price |
$40.86 |
| Previous Close |
$40.42 |
| Change ($) |
0.44 |
| Change (%) |
1.09% |
| Day's Open |
40.39 |
| Day's Range |
39.32 - 40.95 |
| Day's Volume |
670,076 |
| 52-Week Range |
15.25 - 41.37 |
More Stats
| Market Cap |
1.41B |
| Enterprise Value |
1.28B |
| Earnings Date (est) |
Aug 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
39.12M |
| Float |
24.66M |
| EPS (basic) |
-2.75 |
| EPS (diluted) |
-2.71 |
| FCF / Share |
-2.84 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.98M |
| Short Ratio |
7.26 |
| Short % of Float |
12.94% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
36.13 |
| PB Ratio |
8.59 |
| Revenue |
39.04M |
| Operating Income |
-81.69M |
| Net Income |
-81.43M |
| Free Cash Flow |
-95.41M |
| Net Cash |
128.97M |
| Net Cash / Share |
3.74 |
| Gross Margin |
18.78% |
| Operating Margin |
-209.24% |
| Profit Margin |
-208.60% |
| FCF Margin |
-244.39% |
| ROA |
-27.10% |
| ROE |
-53.61% |
| ROIC |
-119.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
8 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$45.38*
(11.06% upside)
Low
42.0
Current: 40.86
High
50.0
Target: 45.38
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 13.82 | 0.71 | 0.13 | - |
| Revenue Growth | 1854.74% | 452.34% | - | - |
| Gross Profit | 7.33 | 0.35 | 0.01 | - |
| Operating Income | -80.60 | -32.14 | -18.17 | -17.48 |
| Net Income | -79.94 | -32.48 | -18.06 | -17.40 |
| Shares Outstanding | 28.57 | 7.00 | 2.56 | 2.31 |
| Earnings Per Share | -2.80 | -4.64 | -7.04 | -7.52 |
| Operating Cash Flow | -83.45 | -31.37 | -18.18 | -17.34 |
| Capital Expenditures | -1.34 | -1.23 | -1.04 | -0.29 |
| Free Cash Flow | -84.79 | -32.60 | -19.21 | -17.63 |
| Cash & Equivalents | 184 | 158 | 24.40 | 8.21 |
| Total Debt | 25.39 | 23.51 | 0.14 | 0.30 |
| Net Cash / Debt | 158 | 134 | 24.26 | 7.91 |
| Assets | 220 | 172 | 29.41 | 10.86 |
| Liabilities | 36.82 | 28.63 | 2.54 | 1.79 |
| Book Value | 183 | 143 | -97.49 | -62.58 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Axonics Modulation Technologies, Inc. |
| Country |
United States |
| Employees |
302 |
| CEO |
Raymond Wayne Cohen |
Stock Information
| Ticker Symbol |
AXNX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NASDAQ: AXNX |
Description
Axonics Modulation Technologies, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems in the United States and internationally. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence, and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company was formerly known as American Restorative Medicine, Inc. and changed its name to Axonics Modulation Technologies, Inc. in August 2013. Axonics Modulation Technologies, Inc. was incorporated in 2012 and is based in Irvine, California.